what does it mean?

The main purpose of this study sponsored by Acorda Therapeutics, Inc is to see if taking dalfampridine-ER tablets twice daily is safe and has an effect on walking abilities in people who have had a stroke. This will be measured by tests of walking and balance, questionnaires, and routine safety tests.

How long is the study?

The study may involve 12 weeks and longer depending on if you participate on the open-lable phase, The time you will spend in the study will depend on the number of days you are able to complete

How to participate?

Please take your time to make your decision about taking part. You may discuss your decision with your friends and family. You can also discuss it with your health care team. If you have any questions, you can ask your study doctor for more explanation.

You must be..

≥ 6 months from occurrence of most recent ischemic stroke

18 Years and older

evidence of a stable walking deficit due to an ischemic stroke, as judged by the Investigator

But cannot be..

History of seizures, except simple febrile seizures

Suicide attempt within 1 year prior to the Screening Visit, or severe suicidal ideation within 6 months prior to the Screening Visit, or subject is at significant risk of suicidal behavior in the opinion of the Investigator

Previous use of AMPYRA, dalfampridine, fampridine or 4-aminopyridine (4-AP)

Initiation of a serotonin reuptake inhibitor (SSRI) within 3 months prior to the Screening Visit, or any change in dosing regimen within 3 months prior to the Screening Visit

Botulinum toxin use within 2 months prior to the Screening Visit

 

if you are interested or someone you know that might be eligible, fill out our survey form here